AlphAIAlphAI — Financial news for AI agents
tradingview.comOCT 151 min read$TAK

Takeda Pharmaceutical Company Limited Stock 12‑Month Price Target Raised to $20.74, Implies 9% Upside

Takeda Pharmaceutical's average stock price target increased from $20.58 to $20.74, with a range of $16.96 to $23.36, according to 14 analysts. This implies a 9% upside based on the Oct. 14 closing price. The consensus rating remains 'Buy' among 17 analysts.

Original reporting
tradingview.com
Published Oct 15, 2026, 4:20 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 15, 2026, 4:29 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Takeda Pharmaceutical Company Limited Stock 12‑Month Price Target Raised to $20.74, Implies 9% Upside — source image
Source · tradingview.com
Decision brief

The 30-second read

$TAKBullishLow
01

Why it matters

The upward revision suggests a slight bullish bias but is unlikely to drive a significant price move.

02

Market read

A routine analyst target update with modest upside; limited trading relevance.

03

What to watch

Potential upcoming earnings or pipeline news could outweigh the target change.

Relevance 4/10Novelty 3/10Timing: today

Background

The article reports a consensus analyst price‑target revision for Takeda Pharmaceutical (TAK) based on 14 analysts' estimates.

Company-level read

Ticker impact

$TAKBullishMedium confidence
Context

Analyst consensus price target raised to $20.74, implying ~9% upside versus the Oct. 14 close.

Expected impact

potential upward pressure as the market prices in the higher target

Evidence & confidence

Price‑target upgrades are routine and modest; they can lift sentiment but lack a catalyst for a large move.

Market effects

Sector

Small positive signal for the pharmaceutical sector as analysts raise expectations for Takeda.

Regional

Limited impact on Japanese equities; Takeda is a major ADR but the change is modest.

Global

Low; the update does not affect broader market trends.

Counterpoint

What could challenge this read

Investors may view the modest target lift as already priced in and hold off on buying.

Key entities

  • company
    Takeda Pharmaceutical Company Limited

    Japanese pharma firm traded in the US as ADR TAK.

Read at source← All news

Related articles

OCT 26
$AZNMedAI 8/10

AstraZeneca: Stomach Cancer Drug With $3 to $5 Billion Sales Potential, and One Significant Wrinkle

AstraZeneca (AZN) reported that its drug sone-ve doubled median survival in stomach cancer patients who had already tried at least two treatments, with median survival rising from 5.0 to 10.0 months. The company expects peak annual sales of $3B to $5B. Takeda (TAK) also reported positive results for its rival drug, arcotatug tavatecan, meeting both primary endpoints.

finance.yahoo.com3 min
OCT 23
$TAKHighAI 9/10

Takeda reports positive phase 3 trial results for gastric cancer drug

Takeda Pharmaceutical (TSE:4502/NYSE:TAK) reported positive Phase 3 trial results for arcotatug tavatecan in gastric cancer patients, meeting overall and progression-free survival endpoints. Median overall survival was 10.2 months vs. 6.9 months for other treatments. The drug showed a 37.4% objective response rate. Takeda plans regulatory filings in Japan and China. The drug is not yet approved by the FDA.

investing.com2 min
OCT 19
$TAKLowAI 8/10

First and Only Ulcerative Colitis Treat-to-Target Trial Shows Treating to Disease Clearance vs. Symptomatic Remission with ENTYVIO® (vedolizumab) Prolongs Time to First Disease-Related Complication

Takeda's VERDICT trial showed that treating ulcerative colitis patients with ENTYVIO to achieve disease clearance (vs. symptomatic remission) prolonged time to complications by 70%. The study met its primary endpoint, with Group 3 (disease clearance) showing longer time to complications (HR 0.33, P=0.0014). Over 50% of patients in Group 3 achieved their target by Week 16. The trial also identified molecular patterns associated with early disease clearance.

elliotlakestandard.ca2 min